NCT00625079View on ClinicalTrials.gov

Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis And Treatment With Sildenafil

PHASE4WithdrawnINTERVENTIONAL
0
Timeline

Start Date

February 28, 2007

Primary Completion Date

June 30, 2009

Study Completion Date

December 31, 2009

Conditions
Pulmonary Arterial HypertensionIdiopathic Pulmonary FibrosisInterstitial Lung DiseasePulmonary Hypertension
Interventions
DRUG

sildenafil

the dose of sildenafil will be 20mg three times per day (orally)

Trial Locations (1)

90095-1690

David Geffen School of Medicine UCLA, Los Angeles

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

University of California, Los Angeles

OTHER